Akoya Biosciences Management

Management Kriterienprüfungen 3/4

Akoya Biosciences CEO ist Brian McKelligon , ernannt in Jul 2017, hat eine Amtszeit von 7.33 Jahren. Die jährliche Gesamtvergütung beträgt $2.92M , bestehend aus 18.6% Gehalt und 81.4% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.075% der Aktien des Unternehmens, im Wert von $78.56K . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 2.4 Jahre bzw. 4.3 Jahre.

Wichtige Informationen

Brian McKelligon

Geschäftsführender

US$2.9m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts18.6%
Amtszeit als Geschäftsführer7.3yrs
Eigentum des Geschäftsführers0.08%
Durchschnittliche Amtszeit des Managements2.4yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder4.3yrs

Jüngste Management Updates

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Akoya Biosciences, Inc.'s (NASDAQ:AKYA) CEO For Now

May 29
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Akoya Biosciences, Inc.'s (NASDAQ:AKYA) CEO For Now

Recent updates

Revenue Downgrade: Here's What Analysts Forecast For Akoya Biosciences, Inc. (NASDAQ:AKYA)

Nov 19
Revenue Downgrade: Here's What Analysts Forecast For Akoya Biosciences, Inc. (NASDAQ:AKYA)

Is Akoya Biosciences (NASDAQ:AKYA) Using Too Much Debt?

Nov 12
Is Akoya Biosciences (NASDAQ:AKYA) Using Too Much Debt?

Akoya Biosciences, Inc. (NASDAQ:AKYA) Stock Rockets 36% But Many Are Still Ignoring The Company

Oct 08
Akoya Biosciences, Inc. (NASDAQ:AKYA) Stock Rockets 36% But Many Are Still Ignoring The Company

Akoya Biosciences, Inc. (NASDAQ:AKYA) Just Reported, And Analysts Assigned A US$5.42 Price Target

Aug 09
Akoya Biosciences, Inc. (NASDAQ:AKYA) Just Reported, And Analysts Assigned A US$5.42 Price Target

Market Might Still Lack Some Conviction On Akoya Biosciences, Inc. (NASDAQ:AKYA) Even After 31% Share Price Boost

Jun 27
Market Might Still Lack Some Conviction On Akoya Biosciences, Inc. (NASDAQ:AKYA) Even After 31% Share Price Boost

Is Akoya Biosciences (NASDAQ:AKYA) A Risky Investment?

Jun 24
Is Akoya Biosciences (NASDAQ:AKYA) A Risky Investment?

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Akoya Biosciences, Inc.'s (NASDAQ:AKYA) CEO For Now

May 29
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Akoya Biosciences, Inc.'s (NASDAQ:AKYA) CEO For Now

Investors Continue Waiting On Sidelines For Akoya Biosciences, Inc. (NASDAQ:AKYA)

May 10
Investors Continue Waiting On Sidelines For Akoya Biosciences, Inc. (NASDAQ:AKYA)

Is Akoya Biosciences (NASDAQ:AKYA) Weighed On By Its Debt Load?

Feb 28
Is Akoya Biosciences (NASDAQ:AKYA) Weighed On By Its Debt Load?

Investors Still Aren't Entirely Convinced By Akoya Biosciences, Inc.'s (NASDAQ:AKYA) Revenues Despite 31% Price Jump

Nov 25
Investors Still Aren't Entirely Convinced By Akoya Biosciences, Inc.'s (NASDAQ:AKYA) Revenues Despite 31% Price Jump

Akoya Biosciences Seeks Growth Despite Higher Operating Losses

May 30

Akoya Biosciences, Inc. (NASDAQ:AKYA) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

May 11
Akoya Biosciences, Inc. (NASDAQ:AKYA) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Brian McKelligon im Vergleich zu den Einnahmen von Akoya Biosciences verändert?
DatumGesamtvergütungGehaltUnternehmensgewinne
Sep 30 2024n/an/a

-US$58m

Jun 30 2024n/an/a

-US$60m

Mar 31 2024n/an/a

-US$68m

Dec 31 2023US$3mUS$543k

-US$63m

Sep 30 2023n/an/a

-US$71m

Jun 30 2023n/an/a

-US$76m

Mar 31 2023n/an/a

-US$73m

Dec 31 2022US$3mUS$518k

-US$71m

Sep 30 2022n/an/a

-US$69m

Jun 30 2022n/an/a

-US$63m

Mar 31 2022n/an/a

-US$51m

Dec 31 2021US$2mUS$393k

-US$44m

Sep 30 2021n/an/a

-US$34m

Jun 30 2021n/an/a

-US$28m

Mar 31 2021n/an/a

-US$28m

Dec 31 2020US$516kUS$350k

-US$22m

Dec 31 2019US$484kUS$333k

-US$18m

Vergütung im Vergleich zum Markt: BrianDie Gesamtvergütung ($USD2.92M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD649.07K).

Entschädigung vs. Einkommen: BrianDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.


Geschäftsführer

Brian McKelligon (55 yo)

7.3yrs

Amtszeit

US$2,919,599

Vergütung

Mr. Brian McKelligon has been Chief Executive Officer and Director at Akoya Biosciences, Inc. since July 2017 and also serves as its President. Prior to joining Akoya, he led corporate and business develop...


Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
Brian McKelligon
President7.3yrsUS$2.92m0.075%
$ 78.6k
John Ek
CFO, Principal Financial Officer & Principal Accounting Officer1.7yrsUS$2.37m0.092%
$ 96.5k
Anthony Catalano
Senior Vice President of Operationsno datakeine Datenkeine Daten
Priyam Shah
Senior Director of Business Development & Investor Relations Strategyno datakeine Datenkeine Daten
Jennifer Kamocsay
Chief Legal Officer1.8yrskeine Daten0.012%
$ 12.9k
Niro Ramachandran
Chief Business Officer4.3yrsUS$365.22k0.29%
$ 305.5k
Pascal Bamford
Senior Vice President of Research & Development and Laboratory Operations3.1yrskeine Daten0.17%
$ 174.6k
Rob Hart
Secretaryno datakeine Datenkeine Daten

2.4yrs

Durchschnittliche Betriebszugehörigkeit

51yo

Durchschnittliches Alter

Erfahrenes Management: AKYADas Führungsteam des Unternehmens gilt als erfahren (2.4 Jahre durchschnittliche Betriebszugehörigkeit).


Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
Brian McKelligon
President7.3yrsUS$2.92m0.075%
$ 78.6k
Robert Shepler
Independent Director9yrsUS$251.66k0.75%
$ 779.8k
Myla Lai-Goldman
Independent Director3.2yrsUS$237.50k0.040%
$ 42.2k
Thomas Schnettler
Independent Director5.2yrsUS$220.00k0%
$ 0
Thomas Raffin
Director9yrsUS$210.00k0.47%
$ 495.0k
Matthew Winkler
Independent Director7.3yrsUS$232.50k1.99%
$ 2.1m
James Allison
Member of Scientific Advisory Boardless than a yearkeine Datenkeine Daten
Scott Mendel
Independent Chairman3.4yrsUS$250.00k0.058%
$ 60.1k
Padmanee Sharma
Member of Scientific Advisory Boardless than a yearkeine Datenkeine Daten
Garry Nolan
Chair of the Scientific Advisory Boardless than a yearUS$220.00k1.24%
$ 1.3m

4.3yrs

Durchschnittliche Betriebszugehörigkeit

66yo

Durchschnittliches Alter

Erfahrener Vorstand: AKYADie Vorstandsmitglieder gelten als erfahren (4.3 Jahre durchschnittliche Amtszeit).